Skip navigation

While cell-free DNA is our business, it’s patients who power our purpose

Natera’s diverse teams blend a passion for patients with deep clinical, scientific, and technological roots.

Steve Chapman

Steve Chapman

Chief Executive Officer

Steve Chapman is Natera’s Chief Executive Officer and serves on the company’s board of directors. During his tenure, he has held a number of leadership roles including Chief Operating Officer. As COO, he led the company’s entry into the highly competitive non-invasive prenatal testing market, in which the company’s Panorama® test became the market leader despite being fourth to market. Mr. Chapman was appointed CEO in January 2019 and has been instrumental in extending Natera’s core technology to address new organ health and oncology markets. This includes driving rapid growth for the Prospera™ transplant assessment test, launching the Renasight™ test which screens for genetic causes of chronic kidney disease, and establishing Natera’s leadership in molecular residual disease testing with Signatera.™ Since becoming CEO, Natera has achieved significant year-on-year revenue growth and has consistently outperformed earnings expectations. Prior to joining Natera, Mr. Chapman worked at Genzyme Genetics, where he was credited with delivering record-breaking growth and strategies that changed pregnancy genetic testing. Mr. Chapman began his career as a researcher in the department of human genetics at UCLA designing arrays identifying SNPs associated with multiple sclerosis. He graduated with honors and holds a B.S. in Microbiology, Immunology, and Molecular Genetics from UCLA.

Read Full Bio +
Mike Brophy, MBA

Mike Brophy, MBA

Chief Financial Officer

Mike Brophy is Natera’s CFO, he joined Natera in 2015 serving as Natera’s Senior Vice President of Finance and Investor Relations, and prior to that as Vice President of Corporate Development and Investor Relations. Prior to joining Natera, he served as an executive director and as a vice president in the investment banking division of Morgan Stanley, where he focused on advising corporate clients in the life science tools and diagnostics sector. Mr. Brophy holds a master’s degree in business administration from the University of California, Los Angeles, and a Bachelor of Science degree in economics from the United States Air Force Academy. His military career included leading a multi-agency, 10-person team on a $1.4 billion contract to modernize 10 remote satellite tracking stations worldwide.

Read Full Bio +
Alexey Aleshin, MD, MBA

Alexey Aleshin, MD, MBA

GENERAL MANAGER, ONCOLOGY AND ECD & CHIEF MEDICAL OFFICER

Alexey Aleshin, MD, general manager of oncology and early cancer detection & chief medical officer, joined Natera in 2017. He has served in many leadership capacities during his tenure at the company including medical director of oncology, vice president of oncology medical affairs and chief medical officer. Prior to Natera, Dr. Aleshin was actively involved as an advisor and consultant at various companies focused on advancing clinical adoption of next generation sequencing technologies. He received his M.D. and M.B.A. from UCLA and later completed his internal medicine residency at Stanford University Medical Center and his hematology/oncology fellowship at Stanford Hospital.
Read Full Bio +
Olesya Anisimova, CPA

Olesya Anisimova, CPA

Chief Accounting Officer

Olesya A. Anisimova, CPA, has served in public accounting and industry for over 15 years. During her career, Olesya’s primary focus was on manufacturing and biotechnology industries. Olesya came from Ernst & Young and started at Natera in February 2015 as an Assistant Controller and was subsequently promoted to Senior Director of Finance & Corporate Controller. Olesya’s role had evolved into VP of Finance and Senior VP of Finance throughout her career at Natera. Since January 2022, Olesya has been serving Natera as the Chief Accounting Officer. Since joining the company in early 2015, Olesya has played a crucial role in the company’s success. She successfully filed Natera’s IPO with the accounting and finance team and is responsible for Natera’s annual and quarterly SEC filings. She has managed a broad range of responsibilities including driving improvements in various operations, performing SEC filings, and SOX compliance controls. She was recently leading on the Company’s new ERP Implementation as well. Olesya continues her role as Chief Accounting Officer for Natera, as well as working closely with the CFO and FPA Team on strategic decisions for company operations.
Read Full Bio +
Jerry Diffley

Jerry Diffley

Chief Compliance and Privacy Officer

Jerry Diffley joined Natera in August of 2017 as its Chief Compliance and Privacy Officer. Mr. Diffley is a seasoned laboratory executive with extensive experience in U.S. and international laboratory compliance, privacy, billing and laboratory operations.

Prior to joining Natera, Mr. Diffley worked at Quest Diagnostics for over 23 years in a variety of operational positions and more recently in its Legal Compliance function. Mr. Diffley holds a B.S. in Education from SUNY Plattsburgh and a Master’s degree in Business and Healthcare Administration from Stony Brook University.

Read Full Bio +
Eric Evans, PhD

Eric Evans, PhD

Chief Scientific Officer

Dr. Eric Evans joined Natera in 2020 as Chief Scientific Officer. Prior to joining Natera, he was co-founder and Chief Scientific Officer of Counsyl for 12 years. In that role, he led R&D and clinical operations for a molecular diagnostics portfolio in women’s health and oncology. He has authored papers in reproductive genetics and molecular diagnostics, including journals such as JAMA, Genetics in Medicine, Clinical Chemistry, and Prenatal Diagnosis. He received his B.S. in Biological Sciences from the University of Delaware and his Ph.D. in Genetics from Stanford University. While at Stanford, he was a Stanford Graduate Fellow working on the genetics of aging and the immune system.

Read Full Bio +
John Fesko

John Fesko

PRESIDENT, CHIEF BUSINESS OFFICER

John Fesko, president, chief business officer, joined Natera in 2014. He leads company-wide efforts across multiple functions and programs, including collaborations with payors, government affairs, business development, market development, pharmaceutical services, patient experience, communications, marketing, and international commercial operations and strategy. Prior to Natera, John worked at Roche, Novartis Pharma AG, MPM Capital and InVivoScribe. He holds an M.B.A. from M.I.T. and a B.S. in biochemistry and economics from the University of Notre Dame.
Read Full Bio +
Ramesh Hariharan, PhD, MBA

Ramesh Hariharan, PhD, MBA

General Manager, Women's Health

Dr. Ramesh Hariharan is responsible for strategy and execution of Natera’s women’s health business. Dr. Hariharan’s career of 24 years spans a range of subspecialties, including basic research, strategic management consulting, and marketing. At GE’s Basic Research Center, he was nominated as the Best Young Scientist for his innovations, which included the discovery of a new molecule that was commercialized to enable higher data densities in rewritable DVDs, and a novel process for agglomerating nanoparticles. At McKinsey, he served biotech, pharma, medical device, diagnostics, and private equity leaders in the U.S., Germany, and the U.K., tackling a wide range of business issues such as product launches, market expansion, life cycle strategies, and business turnarounds. Dr. Hariharan then held marketing leadership positions in Oncology, Women’s Health, and Vaccines at Novartis, Abbott/AbbVie and Biotheranostics. At Biotheranostics, he drove the commercial turnaround of Breast Cancer Index, which resulted in a successful financial exit for the parent company. After Biotheranostics, Dr. Hariharan joined Natera to head the Marketing & Medical Education function and 2.5 yrs later transitioned to lead the Women’s Health business. He received a bachelor’s degree in Chemical Engineering from IIT Bombay, a Ph.D. in Chemical Engineering from Princeton University, and an MBA from MIT Sloan School of Management
Read Full Bio +
Rishi Kacker

Rishi Kacker

Chief Technology Officer

Rishi Kacker serves as Natera’s Chief Technology Officer, bringing 20-years of experience in software, genetics, and health tech entrepreneurship. At Natera he is responsible for leading a team including product, UX, software engineering and IT with the mission to expand access to genetic testing for millions each year through innovations/transformation in the patient and provider experience. Additionally, the team has launched a massive clinico-genomic data and research platform being used to accelerate our knowledge of genetic disease. Prior to Natera, Mr. Kacker was the Chief Technology Officer at Myriad Genetics and co-founder and SVP of Technology at Counsyl (acquired by Myriad Genetics). He started his career as co-founder of Voltage Security, a data security and enterprise software business that was acquired by HP Enterprise. Mr. Kacker holds a B.S. degree in computer science from Stanford University.

Read Full Bio +
J. Dianne Keen-Kim, PhD, FACMG, HCLD (ABB)

J. Dianne Keen-Kim, PhD, FACMG, HCLD (ABB)

CLIA Laboratory Director

As Senior Vice President of Laboratory Affairs & Quality, and Natera’s corporate CLIA Laboratory Director, Dr. Keen-Kim is responsible for the overall operation and administration of the clinical laboratories, as well as Natera’s Quality culture. Since joining Natera in 2018, Dr. Keen-Kim built the genetic variant classification and curation processes, has grown data analysis and clinical reporting operations 4-fold, and provides daily quality oversight and risk management in oncology, women’s health, and transplant diagnostics. With expertise in cell-free DNA, Next Generation Sequencing, and automation technologies, Dr. Keen-Kim earned a bachelor’s degree from Carnegie Mellon University, a Ph.D. from MIT, completed her fellowship at UCLA, and currently serves as an Adjunct Clinical Professor at Stanford University School of Medicine. She is licensed by California and New York to direct medical laboratories and maintains three HHS-approved board certifications. Dr. Keen-Kim is a mentor and champion for women leaders and is passionate about staff training and development to create growth opportunities for the next generation.

Read Full Bio +
Chitra Kotwaliwale, PhD

Chitra Kotwaliwale, PhD

SVP OF CLINICAL & COMMERCIAL OPERATIONS AND PORTFOLIO MANAGEMENT

Chitra Kotwaliwale serves as senior vice president of clinical & commercial operations and portfolio management. She joined Natera in 2019 and has held multiple roles across product management and strategy, overseeing product management for the women’s health team, managing overall strategic planning and PMO for Engineering/R&D, and coordinating global product strategy. Prior to joining Natera, Chitra served as director of product marketing at Agilent Technologies, where she managed the company’s product management team responsible for target enrichment content products for rare diseases and oncology. She previously served as senior product manager of sequencing at Complete Genomics, and prior to that, as a computational biologist at Adaptive Biotechnologies (formerly Squenta, Inc.). Chitra holds a B.A. in biology from the College of Wooster and a Ph.D. in molecular and cell biology from the University of Washington and the Fred Hutchinson Cancer Center. She completed her postdoctoral fellowships at the University of California, Berkeley, which was funded by prestigious fellowships from the Damon Runyon Cancer Research Foundation and Howard Hughes Medical Institute.

Read Full Bio +
Solomon Moshkevich, MBA

Solomon Moshkevich, MBA

PRESIDENT, CLINICAL DIAGNOSTICS

Solomon Moshkevich serves as president, clinical diagnostics, where he oversees productization, clinical validation, commercialization, and quality across the company. Since joining Natera in 2011, Solomon has built and led multiple teams including global marketing, product management, medical and scientific affairs, commercial operations, clinical trial operations, business development, international sales, program management and portfolio strategy; and he has played a leading role in the development, clinical validation and commercial success of all Natera’s cell-free DNA products including Panorama, Prospera, and Signatera. Most recently, Solomon served as general manager of oncology for the company, overseeing a period of tremendous growth and leading the company’s efforts to achieve Medicare coverage for Signatera across multiple cancer types. Solomon began his career as a consultant with Bain & Company in New York before joining the private equity investment team at Parthenon Capital in Boston; and he currently serves on the Board of Directors for the Ronald McDonald House Charities of the Bay Area. He graduated from Columbia University summa cum laude with a B.A. in Economics and Mathematics, and he holds an M.B.A. from Stanford University.

Read Full Bio +
Anu Pai, MS

Anu Pai, MS

Head of R&D Program Management

Anu Pai leads Natera’s R&D Program Office. With more than 25 years of experience in product development and management, Anu joined Natera from Roche Diagnostics where she held various leadership roles in assay development, product and portfolio management, developing and launching PCR-based products for infectious diseases & blood screening, microbiology and cervical Cancer screening. Anu started her career as an R&D scientist working on multiplex PCR Assay for screening HIV, HCV and HBV, she has also managed large scale clinical trials, as well as design control and regulatory processes, having worked on IVD, RUO, IUO and Companion Diagnostics products. Anu holds an M.S in Chemistry from the University of Kentucky.

Read Full Bio +
Sheetal Parmar, MS, CGC

Sheetal Parmar, MS, CGC

SVP of Medical Affairs, Women’s Health

Sheetal Parmar serves as senior vice president of medical affairs for women’s health at Natera. She is a board-certified genetic counselor specializing in prenatal diagnosis and screening. Since joining Natera in 2013, Sheetal has held a number of positions, including senior director of clinical genetic services and director of medical education. Prior to Natera, she worked for 11 years as the lead prenatal genetic counselor at a high-risk prenatal diagnosis clinic and cytogenetic laboratory.

Sheetal serves on the Board of Directors for the National Society of Genetic Counselors (NSGC). In 2020, she accepted the Leading Women Entrepreneur Force for Change Illuminator award for her leadership and contributions to Natera’s positive impact on the lives of others during the COVID-19 pandemic.

Sheetal received her BA in Molecular and Cell Biology from UC Berkeley and her MS in Genetic Counseling from the University of Cincinnati, where she was an Albert C. Yates Scholar and Fellow.

Read Full Bio +
Daniel Rabinowitz, LLM

Daniel Rabinowitz, LLM

Secretary & Chief Legal Officer

Daniel Rabinowitz is Secretary and Chief Legal Officer of Natera. Prior to joining Natera, he was a corporate partner at the law firm McDermott, Will & Emery, and, before that, was also a corporate lawyer at the law firm Davis Polk & Wardwell. He has worked in the United States and Europe advising domestic, foreign, public, and private companies on capital raisings, M&A, investment management and compliance with US federal and state securities law. He has studied genetics, biochemistry, and molecular biology at Harvard University Extension School and attended courses on the legal and ethical aspects of biotechnology at Harvard Law School. Mr. Rabinowitz completed his B.A. and LL.B. degrees at the University of the Witwatersrand, South Africa, graduating at the top of his law school class, and completed his LL.M. at New York University School of Law with both Rotary Foundation and Fulbright Scholarships. Admitted in New York only.

Read Full Bio +
Matthew Rabinowitz, PhD

Matthew Rabinowitz, PhD

Executive Chairman

Dr. Matthew Rabinowitz is co-founder of Natera and currently serves as the Executive Chairman of the board of directors. He served as Natera’s Chief Executive Officer from 2005 to 2019. He serves as a chairman, director or adviser to many companies and nonprofits involved in diagnostics, biotech, AI, health services and nature conservation and manages an early stage technology venture fund focused on biotech, security and AI. Companies he founded have twice received the World Economic Forum Technology Pioneer award, given in those years to 20 companies worldwide, and thrice received Edison Awards in the United States. He has served as consulting professor in Aeronautics and Astronautics at Stanford and visiting faculty in Genetics at Harvard and received the Scott Helt Award from IEEE. He has authored over 100 patents and publications respectively, including papers in the top reproductive, transplant and oncology journals, SCIENCE and Nature (cover). He has led the development of the highest volume clinical genetic test in US history, which transformed pregnancy management; a technology that tracks an individual patient’s tumor mutations in blood that has transformed cancer management with multiple FDA breakthrough designations; and the first whole genome polygenic modelling of embryos to prevent conferring disease risks to our children and other breakthrough products. He was named R&D Leader of the Year by R&D World in 2024. Dr Rabinowitz studied EE and Physics at Stanford, receiving the Levin and Terman awards, the top academic awards offered by each department, and a graduate fellowship to the school of engineering, where he completed a PhD in Electrical Engineering.

Read Full Bio +
John Ryan, PhD, MBA

John Ryan, PhD, MBA

Chief Laboratory Officer

Dr. John Ryan joined Natera as its Chief Laboratory Officer in 2023. Dr. Ryan brings more than twenty eight years of operations experience, with expertise in diagnostic laboratory operations, laboratory partnerships, supply chain management, kit manufacturing and customer service. He most recently served as the Senior Vice President of Operations at Myriad Genetics, overseeing its Neuroscience, Women’s Health, Oncology and International Operations. Dr. Ryan previously served in various roles at Myriad Genetics including Vice President of Hereditary Cancer Operations, Senior Director of Customer Service and Senior Director of Operations. Prior to his time at Myriad Genetics, Dr. Ryan served in the Armed Forces DNA Identification Lab. He obtained a B.A. in Biochemistry and Molecular Biology from the University of California, Santa Cruz, a Ph.D. in Genetics from Stony Brook University and an Executive MBA from the University of Utah David Eccles School of Business.

Read Full Bio +
Robert Schueren

Robert Schueren

Chief Operating Officer

Robert Schueren is an accomplished industry veteran with extensive molecular diagnostics, genomics, and pharma experience. Mr. Schueren has enjoyed an expansive 30-year career and has been a driving force behind rapid business growth at both start-up and large biotech companies. Most recently, he was CEO of IntegenX Inc., playing a critical role in the growth and success of the company, and ultimate acquisition by Thermo Fisher Scientific, as well as successfully leading a lobbying effort to pass the Rapid DNA Act of 2017. Mr. Schueren previously held executive leadership roles including GM of Genomics at Agilent Technologies, Global Head of Clinical Biomarkers and Operations, and Deputy Global Head of Molecular Medicine Labs for Genentech, Inc. He formerly held leadership and commercial roles at Arcturus Bioscience, Accumetrics, Biosite Diagnostics, Gen-Probe, and Abbott Labs. Mr. Schueren received a BS in Pharmacy from Temple University.

Read Full Bio +
Bernie Tobin, MBA

Bernie Tobin, MBA

General Manager, Organ Health

Bernie Tobin is responsible for strategy and execution for Natera’s organ health products. Mr. Tobin is a 25-year veteran of the healthcare industry with his most recent role serving as President of Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics. Crescendo focused on using proteomics to deliver precision medicine to patients with autoimmune disorders.

Previously, Mr. Tobin held several senior-level positions at Amgen including General Manager of both the Netherlands and Brazil and Global Head of Commercial Excellence. In addition, he led the global integration of a business development acquisition in over 100 countries. Prior to that, Mr. Tobin held a variety of leadership roles in the commercial organization at Eli Lilly and Co.  He received his B.S. degree in Public Service and Administration from Iowa State University and his M.B.A. from the Fuqua School of Business, Duke University.

Read Full Bio +
icon-angle icon-bars icon-times